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The Tat protein of the human immunodeficiency virus (HIV) is a powerful activator of HIV gene expression. Genetic and
biochemical evidence suggests that one or more cellular cofactors may be important for Tat activity. We have used two-
hybrid interactive cloning in yeast to identify a partial cDNA clone (clone 10) from a human B-lymphoblastoid library that
specifically interacts with the N-terminal 31 amino acids of HIV-1 Tat which contains the essential cysteine-rich portion of
the Tat activation domain. The encoded protein also binds to purified Tat in vitro. Mutation of single essential cysteine
residues in Tat abolishes interaction between Tat and clone 10, suggesting that interaction with the encoded protein is
important for Tat activity. We have identified the full-length cDNA for the Tat binding protein and shown that overexpression
of the encoded protein, Tip60 (Tat interactive protein, 60 kDa), results in a fourfold augmentation of Tat transactivation of
the HIV-1 promoter in transient expression assays without increasing the basal activity of the HIV promoter or activating
the heterologous RSV promoter. These data together with the genetic and in vitro binding data support the notion that Tip60
might be a cofactor of Tat involved in the regulation of HIV gene expression. q 1996 Academic Press, Inc.
INTRODUCTION land, 1988; Garcia et al., 1989; Muesing et al., 1987; Selby
et al., 1989). The primary function of this RNA target,
The Tat protein of the human immunodeficiency virus-
termed TAR (transactivating response region), is to target
1 (HIV-1) is a powerful transactivator of HIV gene expres-
Tat to the promoter (Selby and Peterlin, 1990; Southgate
sion and is required for replication of HIV (Arya et al.,
and Green, 1991). We and others have shown that active1985; Sodroski et al., 1985). The mechanism of Tat trans-
Tat fusion proteins can be targeted upstream of a pro-activation has been a subject of intense research and is
moter and that Tat transactivation is dependent on thestill somewhat controversial (Cullen, 1993), partly be-
presence of binding sites for cellular transcription fac-cause the HIV promoter directs the synthesis of high
tors, most notably Sp1 (Kamine and Chinnadurai, 1992;levels of short RNA transcripts (Kao et al., 1987; Laspia
Kamine et al., 1991; Southgate and Green, 1991). Onceet al., 1989; Ratnasabapathy et al., 1990; Toohey and
targeted to the promoter, Tat might directly interact withJones, 1989). Therefore, Tat in principle could be acting
Sp1 (Jeang et al., 1993) or basal transcription factorsby a variety of mechanisms to increase the expression
(Kashanchi et al., 1994).of full-length RNA transcripts. Besides increasing tran-
Tat transactivation of the HIV-1 LTR in transient expres-scriptional initiation, Tat could increase the elongational
sion assays shows a strong species tropism. In bothefficiency of transcription or the antitermination of HIV
rodent cells and avian cells the level of Tat transactiva-transcripts. A unique feature of Tat transactivation is the
tion is very low in comparison to that achieved in humanuse of a downstream promoter targeting mechanism
cells (Madore and Cullen, 1993; Newstein et al., 1990).(Muesing et al., 1987; Rosen et al., 1985). Unlike conven-
Likewise, the Tat protein of equine infectious anemiational transcriptional activators which are targeted up-
virus (EIAV) is very active in equine cells but has onlystream of a promoter via DNA binding sites, Tat is tar-
marginal activity in human cells (Carroll et al., 1991).geted to the HIV promoter by direct binding to the stem –
Analysis of human–mouse hybrid cell lines has demon-loop structure at the 5* end of the nascent RNA tran-
strated that only cell hybrids containing human chromo-scripts initiated from the HIV promoter (Feng and Hol-
some 12 restore high levels of Tat activity (Alonso et al.,
1992; Hart et al., 1989; Newstein et al., 1990). This spe-
The Tip nucleotide sequence reported in this article has been submit- cies tropism can be overcome if a Tat–Rev fusion proteinted to the GenBank data base and assigned Accession No. U40989.
is targeted to the HIV promoter by the Rev RNA binding1 To whom correspondence and reprint requests should be ad-
dressed. site (Madore and Cullen, 1993), indicating that the spe-
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cies-specific factor might be involved in promoting Tat partial cDNA clone that encodes a protein that specifi-
cally interacts with the cysteine-rich region of the Tatinteraction with TAR RNA.
Genetic experiments have supported the notion that activation domain. The encoded protein, Tip (Tat inter-
active protein), also binds to purified Tat in vitro. We havecellular factors are also necessary for Tat transactivation.
These studies have used competition experiments be- identified the full-length cDNA for Tip and shown that
overexpression of the encoded 60-kDa protein, Tip60,tween different Tat transactivators to inhibit Tat transacti-
vation. In transient expression assays, the Tat protein of can augment Tat transactivation of the HIV-1 promoter
fourfold in transient expression assays.EIAV could inhibit HIV-1 Tat-mediated transactivation of
the HIV-1 LTR (Carrol et al., 1992; Madore and Cullen,
1993). HIV-1 Tat can also inhibit transactivation by a Tat – MATERIALS AND METHODS
Rev fusion protein targeted to the HIV promoter by the
Yeast two-hybrid selectionRev RNA binding site (Madore and Cullen, 1993). These
competition experiments between different Tat transacti- A human B-cell cDNA library tagged with the Gal4
vators suggest that the activation domain of Tat interacts activation domain, cloned into the lambda phage cDNA
with a cellular cofactor that is necessary for Tat transacti- expression vector system, l-ACT (Durfee et al., 1993),
vation. was obtained from Steve Elledge. The construct,
There have been several reported attempts to isolate pMA424-Tat1-31 (HIS3) (Ma and Ptashne, 1987), contains
cellular proteins that might serve as cofactors for Tat. A the coding sequences for the N-terminal 147-amino-acid
cDNA clone was isolated from a lambda gt11 fusion li- DNA binding domain of GAL4 fused to coding sequences
brary by utilizing a biotinylated Tat probe (Nelbock et al., for the N-terminal 31 amino acids of Tat. Yeast cells,
1990). This protein, designated TBP1 (Tat binding protein strain GGY1::171, which contains an integrated copy of
1), is a 46-kDa nuclear protein that was initially described the GAL1-lacZ gene, were cotransformed with pMA424-
as suppressing Tat transactivation in cotransfection ex- Tat1-31 (HIS3) and pACT-cDNA (LEU2) by the LiAc tech-
periments (Nelbock et al., 1990). TBP1 appears to be a nique (Schiestl and Gietz, 1989) and clones containing
member of a family of evolutionarily conserved genes both plasmids were selected on SC plates (minus leucine
(Shibuya et al., 1992; Swaffield et al., 1992). and minus histidine). After a 3- to 4-day incubation at
In another approach, a 36,000-dalton cellular protein 307, colonies were transferred to nitrocellulose filters,
was isolated from human T-lymphocytes (molt3) by virtue permeablized on the filters by freeze thawing, and as-
of its binding to Tat (Desai et al., 1991). The cDNA for sayed for lacZ activity during 6-hr assays at 307 (Breeden
this protein has recently been cloned and the encoded and Nasmyth, 1985). Positive blue colonies were picked
protein, designated TAP (Tat-associated protein), has and transferred to His0 and Leu0 plates. The colonies
been shown to associate with Tat in vivo and to have a (His/, Leu/) on these secondary plates which gave blue
cryptic transcriptional activation domain (Yu et al., 1995). color in the X-gal filter assay were picked and grown in
Although a Gal–TAP fusion protein that is targeted up- SC medium. Plasmid DNA was isolated from one of these
stream of a promoter–CAT construct can synergistically colonies (clone 10) and used to electroporate LeuB0
interact with Tat to activate transcription, as Tat has been Escherichia coli (strain MH4) to recover the positive
shown to do with other upstream promoter elements pACT-10 cDNA construct. This plasmid was used in two-
(Berkhout et al., 1990; Kamine et al., 1991; Southgate and hybrid assays with pMA424, pMA424-Tat1-31, and addi-
Green, 1991), it has not been demonstrated that TAP is tional pMA424 constructs expressing a number of heter-
a specific Tat cofactor. ologous proteins to determine the Tat binding domain
Another candidate Tat cofactor has recently been iden- and the specificity of binding to Tat. The cDNA insert
tified using the two-hybrid system in yeast (Fridell et was cut out from the plasmid by digestion with XhoI,
al., 1995). Although the protein encoded by the cDNA, cloned into Bluescript, and sequenced using the Seque-
designated HT2A, appears to specifically interact with nase method.
the activation domain of the Tat proteins of HIV-1, HIV-
2, and EIAV in two-hybrid systems in yeast and in mam- In vitro binding assays
malian cells it has not been shown to directly bind to
Tat or to functionally interact with Tat in vivo or in vitro. The cDNA insert of pACT-10 was PCR amplified with
EcoRI and SalI termini and cloned, in frame, into theLikewise, a Tat-associated kinase activity has been
shown to interact with the activation domains of the three EcoRI and SalI sites of the pET22b expression vector
(Novagen). pET22b has an upstream consensus in framelentivirus Tat proteins above (Hermann and Rice, 1995),
but its relationship to HT2A and its functional signifcance ATG and expresses cloned inserts under the control of
the T7 RNA polymerase promoter. RNA was expressedin Tat transactivation have still not been established.
We have used the two-hybrid protein method in yeast using T7 RNA polymerase and translated with [35S]-
methionine using a nuclease-treated rabbit reticulocyteas described by Fields and Song (1989) to identify a
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lysate in a linked transcription–translation system (TNT, L. K. Venkatesh), generating pCMVTIP60. pCMVTIP60 or
the negative control parental expression vector, pCMV,Promega). To determine if the encoded protein could
bind directly to Tat, in vitro binding assays were per- was transfected into HeLa cells via CaPO4 –DNA copre-
cipitation along with pLTRCAT (Kamine et al., 1991),formed between GST–Tat fusion proteins and radiola-
beled Tip synthesized from pET-clone10. Tat coding se- which expresses the CAT (chloramphenicol acetyltrans-
ferase) gene (Gorman et al., 1982) under the control ofquences from the SF2 strain of HIV were fused in frame
by PCR with the bacterial glutathione-S-transferase (GST) the HIV-1 promoter, and pCMVTAT. pCMVTAT expresses
the HIV-1 (SF2 strain) Tat gene under the control of thegene in the pGex-2T expression vector (Pharmacia).
GST–Tat recombinant fusion proteins were induced with CMV immediate early promoter and was constructed by
inserting the Tat gene and poly(A) addition signal (BlgIIIPTG and isolated on glutathione–Sepharose beads as
described by Kaelin et al. (1991). Binding assays were to SalI) from pTat (Peterlin et al., 1986) into pgTat (Malim
et al., 1989). HeLa cells (3 1 105) were plated on 60-mm2performed in binding buffer containing 20 mM HEPES,
pH 7.7, 50 mM KCl, 2.5 mM MgCl2 , 10% glycerol, and 1 culture dishes and cotransfected with 5 mg of pLTRCAT
and 0, 2, 5, or 12 ng of pCMVTAT and 0, 1, or 2 mg ofmM DTT. After 1-hr binding assays at 47, the GST–Tat
complexes bound to the glutathione–Sepharose beads pCMVTIP60. In each transfection, the amount of pCMV
expression vector was adjusted to 2 mg with the parentalwere washed in RIPA buffer and bound complexes eluted
by boiling in Laemmli sample buffer then loaded on an expression vector, pCMV.
10% PAGE–SDS gel.
RESULTS
Lambda library screening for full-length Tip
Identification of a cDNA clone for a cellular protein
A lambda gt11 cDNA library from the HUT-78 T-cell that specifically interacts with Tat in yeast
line (5* stretch library, Clontech, Inc.) was screened with
In the two-hybrid selection system that we have useda labeled PCR probe using specific primers from the
(Fields and Song, 1989) a target plasmid expressing theclone 10 sequence. The 5* end of the PCR primers were
DNA binding domain of Gal4 fused to the target se-at positions 245 and 595 from the 5* end of the yeast
quence of interest is used to target the fusion protein viaclone 10, generating a 350-bp probe. Phages from posi-
the Gal4 DNA binding sites of the UASG yeast regulatorytive plaques were purified and the cDNA insert was
region upstream of the E. coli lacZ reporter gene whichcloned into a Bluescript (KS) vector and sequenced using
is under the Gal1 promoter. Cotransfection of a secondthe Sequenase method. The clone 10 cDNA sequences
construct that contains the activation domain of Gal4were recombined with the lambda gt11 library cDNA se-
fused to sequences from a cDNA library can activatequences in the Bluescript (KS) vector via an internal EagI
lacZ expression if Tat and the sequences encoded bysite to reconstruct the full-length cDNA for TIP60. Sense
the cDNA can interact, resulting in the production of blueRNA was transcribed with T3 RNA polymerase and trans-
colonies. Activation of lacZ activity in transfected cloneslated in a linked transcription–translation system (Pro-
can be identified as blue colonies on X-gal filter assays.mega).
We reasoned that the N-terminal 48 amino acids of
Tat which constitute the activation region of Tat wouldNorthern blot analysis
be a suitable target to search for proteins that interact
Four micrograms of poly(A)/ RNA (Fast Track, In- with Tat. This activation domain of Tat functions automa-
vitrogen, San Diego) from the indicated cell line was run mously and activates transcription when targeted to a
on a 1% agarose–formaldehyde gel and transferred to promoter via a heterlogous DNA binding domain (Kamine
nitrocellulose. Molecular weight standards were from an et al., 1991; Southgate and Green, 1991). Since the full
RNA ladder (Bethesda Research Labs). The blot was first activation domain of Tat activates the GAL1 promoter
probed with 2.5 1 107 dpm of an antisense 32P-labeled in yeast (Subramanian et al., 1994) (Table 1) we used
riboprobe against the clone 10 cDNA. The antisense subregions of the Tat activation domain as targets in the
probe was generated from a Bluescript vector containing two-hybrid system. pMA424-Tat1-31, which contains the
the clone 10 insert using T3 RNA polymerase. Blot was N-terminal 31 amino acids of Tat, was found to be incapa-
then stripped and reprobed with a 1 1 107 dpm of a 32P- ble of activating lacZ activity by itself (Subramanian et
labeled random primed probe against a g-actin molecu- al., 1994) (Table 1); however, when pMA424-Tat1-31 was
lar clone. used to screen a cDNA library fused to the activation
domain of Gal4 (pACT-cDNA) a number of positive blue
Transfections
colonies were detected against the background of white
colonies in the X-gal filter assay. These blue coloniesThe complete Tip 1.9-kb cDNA from pKSTIP60 was
cloned downstream of the CMV immediate early pro- were picked and after a secondary X-gal screening on
His0 and Leu0 selective plates, the pACT-cDNA plasmidmoter in the pCMVT7HA expression vector (supplied by
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TABLE 1 ative for interaction with pACT-10 (Table 1). Two-hybrid
assays were also carried out in yeast strain SF572. InlacZ Expression by Yeast Transformants in the Two-Hybrid System
this strain, the resident lacZ gene is under the control of
lacZ the CYC1 promoter instead of the GAL1 promoter, as in
expression the GGY::171 yeast strain. The SF572 strain has been
utilized to eliminate false positives sometimes associ-
Relative b-
ated with the GGY1::171 strain in the two-hybrid assay.Target Activator gal activity
When the SF572 strain of yeast was transfected with
Yeast stain GGY1::171 pMA424 and pACT-10 only white colonies were pro-
pMA424 pACT 0 duced; however, when pMA424-Tat1-31 was transfected
pMA424 pACT10 0 with pACT-10 an intense blue color was readily evident
pMA424-Tat1-48 pACT //
(Table 1). This result substantiates the previous resultsPMA424-Tat1-48 pACT10 ////
utilizing the GGY1::171 yeast strain.pMA424-Tat1-31 pACT 0
pMA424-Tat1-31 pACT10 /// Interaction of pACT-10 with the entire activation region
pMA424-Tat31-48 pACT10 0 was then examined using a target expressing the N-
pMA424-Rev pACT10 0 terminal 48 amino acids of Tat. We have observed that
pMA424-Rex pACT10 0
the Gal(1-147)/Tat(1-48) chimeric gene can mediate effi-pMA424-Tax pACT10 0
cient transactivation of the GAL1 promoter in yeast strainpMA424-E1b-19K pACT10 0
pMA424-Tat1-48(41) pACT / GGY1::171 (Subramanian et al., 1994) (Table 1). There-
pMA424-Tat1-48(41) pACT10 //// fore, we used a Tat 1-48 target containing the single
pMA424-Tat1-31(22) pACT10 0 amino acid substitution Tat1-48(41) at amino acid residue
pMA424-Tat1-31(30) pACT10 0
41 (lysine(41)  Thr). Mutation of residue 41 in the con-
Yeast strain SF572 served ‘‘core region’’ of Tat (residues 37–47) is known to
pMA424 0 inactivate Tat. The Tat1-48(41) target exhibited a much
pMA424-Tat1-31 ////
reduced level of transactivation and additional increases
in transactivation due to two-hybrid interactions can beNote. The indicated yeast strain was transformed with the indicated
target plasmid and either the control construct, pACT, which expresses readily assessed (Table 1). In cells expressing the Tat1-
only the Gal4 activation domain or pACT-10, which was recovered from 48(41) target and clone pACT-10 there was much more
an initial pACT-cDNA library screen in the yeast two-hybrid system lacZ expression than in cells expressing Tat1-48(41) and
with pMA424-Tat1-31. lacZ activity was either detected by X-gal filter
the control vector DNA (pACT) (Table 1). These resultsassays by blue colony formation or quantitated by b-galactosidase
and the in vitro binding data (see below) indicate thatactivity in liquid culture medium as described (Subramanian et al.,
1994). Minus indicates colonies remained white after X-gal staining for the protein coded by clone pACT-10 efficiently interacts
more than 12 hr; //// indicates intense color development within 1 with the full-length Tat activation domain but that muta-
hr which was greater than 10-fold faster than color development by tions of the core region do not affect Tip binding to Tat.
colonies designated /.
The conserved cysteine-rich domain of Tat is involved
in interaction with pACT-10
DNA was isolated from each clone. This DNA was used
Mutation of either of the two cysteine residues at posi-to transform the yeast indicator strain with either the
tions 22 or 30 in the cysteine-rich domain of Tat elimi-control construct pMA424 or pMA424-Tat1-31. One of
nates interaction of pACT-10 with pMA424-Tat1-31. Sub-the clones, clone 10, designated pACT-10, produced an
stitution of a glycine for the cysteine at position 22 ofintense blue color selectively with pMA424-Tat1-31 but
Tat (pMA424-Tat1-31(22)) or position 30 (pMA424-Tat1-not pMA424 (Table 1).
31(30)) gave only white colonies in the two-hybrid assay
with pACT-10 (Table 1). Therefore, the essential cysteineThe pACT-10 clone specifically interacts with Tat in
region of Tat appears to be part of the binding domainthe two-hybrid system
for interaction with clone 10. This is an important demon-
stration because mutation of either of these two cys-lacZ expression was not activated when a number of
heterologous proteins were used in place of Tat coding teines in native Tat abolishes Tat activity. The correlation
of Tat activity with the ability to bind to the interactivesequences in pMA424. The two-hybrid assays with
pACT-10 and the individual pMA424 constructs indicated yeast clone strongly suggests that interaction of pACT-
10 to Tat is an important function for Tat activity.that the HIV-1 Rev protein, the HTLV-1 Rex and Tax regu-
latory proteins, as well as the adenovirus E1B 19K could
cDNA for Tipnot substitute for Tat and activate lacZ expression in the
two-hybrid system (Table 1). In addition, DNA coding for The clone 10 cDNA is 1581 nucleotides long and con-
tains a long open reading frame that starts at the 5* endTat amino acids 31–48 (pMA424-Tat31-48) was also neg-
/ 6a10$$7712 01-27-96 00:05:21 viras AP-Virology
361CELLULAR BINDING PROTEIN OF HIV-1 TAT
believed to function in silencing the HMR locus (Genbank
Accession No. U14548). The Tip sequence also has sev-
eral regions suggesting potential phosphorylation sites.
The most suggestive site is an Arg–Lys–Asn–Lys–Ser
amino acid motif between nucleotides 890 and 904 of
the Tip cDNA sequence (Fig. 1A). The two basic residues
followed by two intervening residues and then a serine
are very characteristic of a cAMP-dependent protein ki-
nase phosphorylation site (Czernik, 1991), suggesting
that Tip might be a phosphoprotein. We have identified
the 5* end of the cDNA for Tip by two independent
lambda gt11 cDNA library screenings: a PMA-activated
HUT-78 T-cell library and a Raji B-cell library (both 5*
stretch, Clontech, Inc.) using specific primers from the
clone 10 sequence. The 5* end of the full-length clone
extends 364 nucleotides beyond the 5* end of clone 10,
giving a total composite cDNA length of 1945 nucleo-
tides. The sequence and structure of the full-length cDNA
for Tip is shown in Fig. 1.
The composite 1.9-kb full-length cDNA for Tip was
cloned into the Bluescript (KS) vector via an internal EagI
site to generate pKSTIP60. RNA was transcribed with
T3 RNA polymerase and translated in a linked transcrip-
tion–translation system (Promega). A 60,000-dalton
[35S]methionine-labeled protein was synthesized with
pKSTIP60 (Fig. 2, lane 2) that was not detected with the
KS vector without insert pKS (Fig. 2, lane 1). The level of
expression of Tip60 from pKSTIP60 is very much lower
than that achieved with the clone 10 cDNA fused to an
in-frame heterologous ATG in the pET expression vector
system (compare Fig. 2 to Fig. 4B, lane 1). Interestingly,
there is no in-frame ATG within the first 600 nucleotides
of the Tip cDNA sequence. There is, however, an in-
frame CTG triplet in a favorable Kozak context at the start
of the cDNA (nucleotides 65–67); this is the only in-frame
CTG in a favorable Kozak context within the first 600
FIG. 1. Tip cDNA. (A) Sequence of full-length cDNA for Tip. (B) Struc-
ture of the full-length cDNA for Tip. Composite of the cDNA sequences
from clone 10 combined with the contiguous 5* cDNA sequences iso-
lated from a lambda gt11 cDNA library from HUT-78 cells. The full-
length clone extends 364 nucleotides beyond the 5* end of the yeast
clone 10.
of the clone and extends for 1146 nucleotides. The size
of the inferred protein product is 383 amino acids with
a molecular mass of 44,000 daltons (Fig. 1B). We have
designated this encoded amino acid sequence Tip, for
Tat interacting protein. The clone 10 cDNA contains a
poly(A) addition signal and a stretch of 15 adenosine
FIG. 2. In vitro translation of Tip60. Full-length Tip cDNA was clonedresidues at its 3 * end (Fig. 1A). There is only one exten-
into the Bluescript (KS) vector (pKSTIP60) and coupled in vitro transcrip-sive sequence homology in the Gen/EMBL Protein Data
tion/translation assays were carried out using T3 RNA polymerase and
Base. A 175-amino-acid region of Tip shares a 40% se- nuclease-treated rabbit reticulocyte lysates (TNT, Promega). [35S]-
quence identity with a yeast protein, Sas2p. The function Methionine-labeled products from either pKSTIP60 or the parental vec-
tor pKS were resolved on 10% PAGE.of Sas2p in yeast has not been documented but it is
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amounts of the 2-kb g-actin mRNA (Fig. 3B). These data
suggest that Tip is expressed in roughly equivalent
amounts in various cell types.
Tip binds to Tat in vitro
To extend and confirm our results on Tip and Tat inter-
action in yeast, we examined if Tip could directly bind to
Tat in vitro. In vitro binding assays were performed be-
tween GST–Tat fusion proteins and the radiolabeled Tip
protein encoded by clone 10 and inserted into pET (pET-
clone10). SDS–PAGE analysis of the [35S]methionine-la-
FIG. 3. Northern blot of Tip-specific poly(A)/ RNA. Four micrograms beled proteins shows that the pET-clone10 construct syn-
of poly(A)/ RNA from the indicated cell line was run on a 1% agarose–
thesized large amounts of a single protein of 45,000 dal-formaldehyde gel and transferred to nitrocellulose. Northern blot was
tons (Fig. 4A, lane 1). This protein represents the partialprobed with (A) 2.5 1 107 dpm of an antisense 32P-labeled riboprobe
against the clone 10 cDNA. The antisense probe was generated from Tip protein encoded by the cDNA recovered in the two-
a Bluescript vector containing the clone 10 insert using T3 RNA poly- hybrid assay in yeast. Tip showed no binding to a control
merase. The autoradiogram was exposed for 7 days. Molecular weight GST protein (Fig. 4A, lane 2); however, Tip bound to GST–
standards were from an RNA ladder (Bethesda Research Labs). The
Tat1-101, which contains the full-length 101 amino acidsTip-specific RNA is approximately 1.9 kb. (B) Blot was stripped and
of the wild-type Tat protein of the SF2 strain of HIV-1 (Fig.reprobed with a 1 1 107 dpm of a 32P-labeled random primed probe
against g-actin molecular clone. The autoradiogram was exposed for 4B, lane 3). A negative control protein, [35S]methionine–
2 days. The expected size of the g-actin mRNA is 2 kb. luciferase (Fig. 4A, lane 4), showed no binding either to
GST (Fig. 4A, lane 5) or to the GST–Tat1-101 fusion pro-
tein (Fig. 4A, lane 6). Therefore, Tat and Tip can directlynucleotides of the cDNA. Initiation from this CTG codon
interact.would generate a Tip protein of 55,000 daltons. There
GST–Tat1-48, which contains the N-terminal 48 aminoare a number of examples of such CTG codons utilized
acids, and hence has the full activation region of Tat,in place of ATG to specify an initiation methionine (Carroll
also bound quite strongly to [35S]methionine Tip (Fig. 4B,and Derse, 1993; Florkiewicz and Sommer, 1989; Hann
lane 4) but not to the GST control (Fig. 4B, lane 3). Tipet al., 1988,). We have also isolated Tip genomic clones
and find that there is no potential ATG initiation codon
before termination codons upstream of the 5* end of
the Tip cDNA. In addition, we have determined that the
genomic sequences within 250 nucleotides of 5* end of
the Tip cDNA contain a transcriptional promoter when
cloned into the promoterless CAT construct pCAT3M
(data not shown). This promoter does not contain a TATA
box but has a number of consensus binding sites for
transcription factors, including Sp1 (data not shown).
These data together with the 1.9-kb size of Tip cellular
mRNA (see below) suggest that we have isolated the
full-length cDNA for Tip and that an ATG triplet does not
specify an initiator methionine for the 60,000-dalton Tip
FIG. 4. Binding of radiolabeled Tip to GST–Tat in vitro. (A) Binding
translation product. However, confirmation will require of radiolabeled Tip to full-length Tat (GST–Tat1-101): Lane 1, [35S]-
mapping of the Tip mRNA start site and the determination methionine-labeled 45,000-kDa protein product (Tip) synthesized from
the pET–clone10 construct. lane 2, radiolabeled Tip did not bind to theof the N-terminal sequence of Tip.
GST negative control fusion protein, but did bind to GST–Tat1-101 (laneNorthern blot analysis indicates that Tip-specific
3). A negative control protein, [35S]methionine-labeled luciferase (lanepoly(A)/ RNA is approximately 1.9 kb (Fig. 3A). Poly(A)/
4), showed no binding to either GST or GST–Tat101 (lanes 5 and 6,
RNA was isolated from U937 cells (a monocyte cell line), respectively). (B) Binding of Tip to GST–Tat mutants: Lane 1, [35S]-
H9 and Jurkat cells (both T-lymphocyte lines), and HeLa methionine-labeled Tip synthesized from pET–clone 10. Lane 2, Molec-
ular weight marker. Tip did not bind to the GST-negative control (lanecells (Fig. 3). An antisense 32P-labeled riboprobe against
3), but did bind to GST–Tat1-48 (lane 4). Tip also bound to a GST–the yeast clone 10 cDNA detected equivalent levels of
Tat(D6) mutant lacking the N-terminal six amino acids of Tat (lane 5)1.9-kb poly(A)/ RNA from each of these cell lines (Fig.
but showed a definite reduced binding to GST–Tat(22) with a single
3A). Stripping and reprobing the same blot with a random cysteine to serine point mutation at residue 22 (lane 6). [35S]Methionine-
primed 32P-labeled probe against g-actin mRNA con- labeled luciferase (lane 9) showed no binding to either GST or GST–
Tat1-48 (lanes 7 and 8, respectively) in these assays.firmed that each of the preparations contained equivalent
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also bound quite strongly to GST–Tat (D6), a mutant
lacking the N-terminal 6 amino acids of Tat (Fig. 4B,
lane 5), but showed a definite reduced binding to GST –
Tat(22), which has a single cysteine to serine point muta-
tion at residue 22 of Tat (Fig. 4B, lane 6). The reduction
in binding of GST–Tat(22) to Tip was much less drastic
than the absolute reduction in lacZ activation with the
Tat(22) mutation in the two-hybrid assay, suggesting that
the in vivo assay is more sensitive to Tat mutant pheno-
type than the in vitro binding assay. Under these same
assay conditions, the [35S]methionine–luciferase nega-
tive control (Fig. 4B, lane 9) did not bind to either GST
(Fig. 4B, lane 7) or GST– Tat1-48 (Fig. 4B, lane 8).
Overexpression of Tip in transient expression assays
augments Tat transactivation of the HIV-1 promoter
pCMVTIP60 did not increase the basal level of expres-
sion of the HIV-1 LTR (Fig. 5A), nor did pCMVTIP60 acti-
vate the heterlogous Rous sarcoma LTR linked to the
CAT gene in transient expression assays (Fig. 5B). Like-
wise, overexpression of Tip did not augment activity of
EIAV Tat (which lacks a cysteine-rich region) on the EIAV
promoter in transient CAT assays (data not shown). How-
ever, HIV-1 Tat activity, at 2 ng of pCMVTAT, was in-
creased fourfold with 2 mg of pCMVTIP60. With higher
amounts of pCMVTAT, transactivation of CAT activity in-
FIG. 5. Specific augmentation of Tat transactivation of the HIV-1creased in an approximately linear fashion but augmen-
promoter by overexpression of Tip60. (A) 3 1 105 HeLa cells weretation of Tat transactivation by Tip60 decreased at the
transfected with 5 mg of pLTRCAT and the indicated nanogram amounts
higher concentrations of pCMVTAT. Since we have deter- of pCMVTat and the indicated microgram amounts of either pCMVTIP60
mined that HeLa cells have significant levels of endoge- or pCMV. The CAT activity was measured 48 hr posttransfection and
is expressed as [14C]chloramphenicol acetylated over total [14C]-nous Tip-specific mRNA expression and presumably
chloramphenicol. The fold Tat transactivation is shown and the resul-Tip60 protein expression, the fourfold augmentation of
tant fold increase in Tat transactivation by Tip60 is calculated. (B) HeLaTat transactivation observed would seem to be a signifi-
cells were transfected with 5 mg of RSVCAT and the indicated amounts
cant effect of Tip60 overexpression on Tat activity. of either pCMVTIP60 or pCMV as in (A).
assays results in a fourfold augmentation of Tat transacti-DISCUSSION
vation of the HIV-1 promoter in HeLa cells. This augmen-
tation of Tat transactivation is specific for Tat transactiva-A number of genetic and biochemical observations
have suggested that cellular factors interact with Tat to tion since neither the basal activity of the HIV promoter
in the absence of Tat or the activity of the RSV promoterregulate HIV gene expression (Alonso et al., 1992; Carroll
et al., 1991, 1992; Hart et al., 1989; Madore and Cullen, is increased by overexpression of Tip60. This specific
augmentation of Tat transactivation by Tip60 overex-1993; Newstein et al., 1990). The identification of cellular
proteins that can functionally interact with Tat would be pression implies that the specific binding of Tip60 to Tat
that is observed in yeast and in vitro might be an im-of great importance in understanding the mechanism of
Tat transactivation. Using the two-hybrid system in yeast portant feature for efficient Tat transactivation of HIV
gene expression.we have been able to isolate a cDNA for a protein termed
Tip that interacts with the N-terminal 31 amino acids of Interaction of Tat1-31 with Tip in the two-hybrid system
could be prevented by single amino acid substitutionsHIV Tat. This in vivo interaction is specific since coding
sequences for heterologous proteins cannot substitute of glycine for cysteine at either position 22 or 30 in the
conserved cysteine-rich region of Tat (amino acids 18–for Tat1-31 and single amino acid substitutions in the
activation domain of Tat abolish interaction with Tip. Tip 37). Tip did not interact with the core region of the Tat
activation domain alone, nor did single amino acid sub-has also been shown to specifically bind to Tat in vitro.
Overexpression of Tip60 in transient expression stitutions in the core region block Tip interaction with
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Tat. Therefore, it would appear that only the cysteine- tained at high levels or be tightly regulated. It is also
interesting to note that the greatest augmentation of Tatrich region of the Tat activation domain is involved in
binding Tip. The cysteine-rich domain is one of three transactivation by Tip occurs when the amount of Tat
expression construct is very low in the transfectionessential regions of HIV-1 Tat (Garcia et al., 1988; Kup-
puswamy et al., 1989). The other required regions are assays. This might be especially relevant in some chroni-
cally infected HIV cell lines like the monocyte cell line,the 9-amino-acid arginine-rich basic region which is re-
quired for nuclear localization and for binding to TAR U1, in which low levels of Tat activity appear to be the
limiting factor for the induction of HIV replication (CannonRNA and the 10-amino-acid core region. The function the
core region is unknown. In the case of the cysteine-rich et al., 1994). In principal, up-regulation of Tip levels in
chronically or latently infected cells could be a factor inregion, six of the seven cysteine residues are absolutely
required for HIV-1 Tat activity (Kuppuswamy et al., 1989). the induction of HIV replication in these cells.
Although the cysteine-rich region is known to be essen-
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